Snus

A tin of Kick-Up tobacco-free snus. This brand uses black tea leaves.

Lyft nicotine pouches

One variation of snus is tobacco-free snus, which is in fact a snus substitute rather than snus. This snus-like product uses black tea leaves or other herbs, with salts and flavorings, and has no tobacco content.[16] Like snus, it is available either loose or, more commonly, in bags, which are sometimes known as pods. Even though it is not made from tobacco, most retailers in Sweden will not sell it to people under the age of 18.

Tobacco-free snus was introduced by the Swedish company Nonico with the brand Choice in 2003.[17][18] Swedish Match launched their competing brand Onico in 2006.[19] At first, it was made with corn starch but in 2008, the formula was changed when it was found to cause dental issues due to the sugar created.

Tobacco-free snus have opened up a new market in the EU, where regular snus with tobacco cannot be sold due to regulations.

A nicotine pouch is a white preportioned pouch containing nicotine.[20] It is like snus, but does not contain tobacco leaf.[20] Nicotine pouches use plant fibers with added nicotine instead of tobacco. Since the plant fiber is tasteless, it allows manufacturers to make nicotine pouches in a much broader selection of flavors compared to traditional snus with tobacco. Nicotine pouches are usually longer lasting and have a longer shelf-life than traditional snus.[21] Nicotine pouches are regulated differently around the world. In some countries, like Norway and Canada, their sale in general stores are banned because they are classified as a new nicotine product. In other countries, including many EU countries, they are sold freely, because they do not classify as a tobacco product like snus, due to their lack of tobacco.[22]

Nicotine pouches are available in a broader selection of nicotine strengths than tobaccos snus since the nicotine is added during the production. With tobacco snus, the strength depends on the type of tobacco and the production method since most manufacturers never add any additional nicotine during the production.

Some forms of tobacco consumed in the mouth may be categorized as:

Swedish snus

A moist form of smokeless tobacco which is usually placed under the upper lip, and which does not result in the need for spitting. It is sold either as a moist powder known as loose snus, or packaged into pouches known as portion snus. Snus is often mildly flavored with food-grade smoke aroma, bergamot, citrus, juniper berry, herbs and/or floral flavors. Most Scandinavian snus is produced in Sweden and regulated as food under the Swedish Food Act.[23]

American snus

Available since the late 1990s, this is similar to the Scandinavian form, but usually has a lower moisture content and lower pH, resulting in lower bioavailability of nicotine than Scandinavian varieties, meaning less is available for absorption.[24] American snus is often flavored, e.g., with spearmint, wintergreen, vanilla or fruit (e.g. cherry), and may contain sugar.[25]

Nasal snuff

Mostly English, German, and Scandinavian, this is referred to as luktsnus in Swedish and luktesnus in Norwegian, and as "Scotch snuff" in the US, is a dry, powdered form of snuff. It is insufflated – "sniffed" but not deeply "snorted" – through the nose. It is often mentholated or otherwise scented.

Chewing tobacco

North American and European product, also known as chew (or in some Southern US dialects as chaw or “dip”). It is tobacco in the form of short or long, loose leaf and stem strands (like pipe tobacco or longer), or less commonly of chopped leaves and stems compressed into blocks called plugs, or even finely ground pieces compressed into pellets. A few brands are cut into much finer loose strands, like cigarette rolling tobacco. Chew is placed between the cheek and the gums, or actively chewed. It causes copious salivation, especially when chewed, and due to its irritant (even nauseating) effect on the esophagus, this "juice" usually requires spitting. Chewing tobacco is a long-established North American form of tobacco (derived from traditional use of raw tobacco leaf by Indigenous peoples of the Americas), and is also legal in the European Union. Chewing tobacco is sometimes flavored, e.g. with wintergreen, apple, or cherry.

Dipping tobacco

Also known as dip, spit tobacco or, ambiguously, as moist snuff, this is a common American form of tobacco. It is moist, and somewhat finely ground, but less so than snus. Dipping tobacco (so called because users dip their fingers into the package to pinch a portion to insert into the mouth) is placed between the lower lip or cheek and the gums; it is not used nasally. As with chewing tobacco, salivation is copious, and usually spat out. Dipping tobacco is usually flavored, traditionally with wintergreen or mint, though many other flavorings are now available, while some unflavored brands remain popular. Beginning in the mid 1980s, several brands have packaged American dipping tobacco in porous pouches like those used for many brands of Scandinavian and American snus.

Chema

This Algerian product is a moist tobacco similar to Scandinavian snus in many respects. Outside of Algeria, it is most widely known as "Makla", a name that originates from the Algerian brand "Makla El Hilal", which first produced this type of smokeless tobacco during the French colonization.[26] It is placed in the upper lip in a manner similar to snus; it differs in that it is more finely ground and has an even higher nicotine content and pH level. Sales within the European Union are legal due to its classification as a chewing tobacco. Its safety in comparison to snus has not been studied sufficiently.

Naswar

A central Asian product which is a moist, powdered form of tobacco, often green and sometimes caked with the mineral lime and/or wood ash. It is used like dipping tobacco or put under the tongue, and is pungent and often heavily flavored, e.g. with culinary oils (cardamom, sesame), the fruit lime, menthol, etc.

Snus, dry snuff, and dipping tobacco are distinct products that English speaking people often call snuff but are processed and used in very different ways, each with their own sets of risks.

A study of almost 10,000 Swedish, male construction workers published in the International Journal of Cancer in 2008 found a statistically significant increase in the incidence of the combined category of oral and pharyngeal cancer among daily users of snus.[29] Other studies and opinion pieces in renowned journals, such as the British Medical Journal and The Lancet,[30][31] do not confirm any correlation between snus usage and oral cancer, but one study suggests a probable increased risk of pancreatic cancer as a result of snus use.[32] A pooled analysis of nine prospective studies involving more than 400,000 men and published in the International Journal of Cancer in 2017 found that use of snus was not associated with a greater risk for pancreatic cancer.[33]

Tobacco shop in Neuchâtel, Switzerland in 2020: Advertising for tobacco (here for snus Epok from British American Tobacco) is authorized inside the shop.

The European Union banned the sale of snus in 1992, after a 1985 World Health Organization (WHO) study concluded that "oral use of snuffs of the types used in North America and western Europe is carcinogenic to humans",[34] but a WHO committee on tobacco has also acknowledged the evidence is inconclusive regarding health consequences for snus consumers.[35] Only Sweden and European Free Trade Association (EFTA)-member Norway are exempt from this ban. A popular movement during the run-up to the 1994 referendum for Sweden's EU membership made exemption from the EU sale ban of snus a condition of the membership treaty.

Recent actions by many European governments to limit the use of cigarettes has led to calls to lift the ban on snus, as it is generally considered to be less harmful than cigarette smoke, both to the user [36] and to others.

Recently, the news agency AFP reported that the number of people dying from cancer in the United States has decreased by a third since 1991.[37] The decrease is linked to a reduced use of cigarettes, which is a well-known factor for developing lung cancer. However, no reference is apparently made to snus, or to other forms of cancer.

Europe has a high rate of smoking, with 15 countries qualifying for the top 20 countries in the world for smoking per capita. This is reflected in the statistics on the number of deaths from lung cancer in the EU at 34 per 100,000 inhabitants. Men in the age group 50–54 are over-represented when it comes to deaths from lung cancer.

In Sweden where smoking is relatively uncommon, the number of lung cancer-related deaths is 14 per 100,000 inhabitants. One conclusion is that this is a result of a long snus tradition in the country. It is therefore possible that substitution of cigarettes with snus might save lives. However, snus is highly addictive, and it is associated with various oral cancers, making a policy of replacing tobacco with snus at least problematic.[38]

Since snus is not inhaled it does not affect the lungs as cigarettes, cigars and pipe tobacco do. Because it is steam-pasteurized rather than fire-cured like smoking tobacco or other chewing tobacco, it contains lower concentrations of nitrosamines and other carcinogens that form from the partially anaerobic heating of proteins — 2.8 parts per million for Ettan brand, compared to as high as 127.9 parts per million in some American brands.[39] WHO acknowledges Swedish men have the lowest rate of lung cancer in Europe, partly due to the low tobacco smoking rate, but does not argue for substituting snus for smoking, stating that the effects of snus still remain unclear. Around 2005, several reports, partially funded by the snus industry, indicated that no carcinogenic effects could be attributed to Nordic snus, and this resulted in the removal of the warning label that claimed snus could cause cancer. It was replaced with the more general label "May affect your health negatively". Research is continuing, but no conclusive reports have been made regarding major adverse health effects of snus.

A 2014 report commissioned by Public Health England on electronic cigarettes concluded that snus has a risk profile that includes possible increases in the risk of oesophageal and pancreatic cancer. The report stated that snus use is not associated with an increase in the risk of having a myocardial infarction, but is associated with an increased risk of dying from one if a person does have one. The report also concluded that there is no increased risk of COPD or lung cancer.[40]

Snus manufacturer Swedish Match filed a modified risk tobacco product (MRTP) application with the U.S. Food and Drug Administration (FDA) Center for Tobacco Products to modify the warning label requirements by:[41]

1. removing the current warnings, "This product can cause mouth cancer" and "This product can cause gum disease and tooth loss."
2. replacing the current warning, "This product is not a safe alternative to cigarettes”, with "No tobacco product is safe, but this product presents substantially lower risks to health than cigarettes."
3. retaining the current warning, "Smokeless tobacco is addictive."

The FDA's Tobacco Products Scientific Advisory Committee voted against the request in April 2015 but Swedish Match is continuing their efforts for this change.[42]

R. J. Reynolds has also filed an MRTP application with the FDA for its Camel snus product. As of May 2018, the FDA has yet to issue a ruling.[43]

Medical journal The Lancet [44] published a major study, "Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016", in November 2017. The scientific conclusions with regards to snus was the following. "There is sufficient evidence that chewing tobacco and other products of similar toxicity cause excess risk of oral and oesophageal cancer while, at this time, existing evidence does not support attributing burden to snus or similar smokeless tobacco products." ...while for snus or snuff we did not find sufficient evidence of a RR (relative risk) greater than one for any health outcome." A relative risk [RR] of 1.0, means you are average — [there is no difference in risk between the control and experimental groups]".[45]

During pregnancy[46] and breastfeeding,[47] mothers are advised not to use any products containing nicotine,[48] which harms the fetus.[49]

Scandinavian snus is regularly available, refrigerated, in the United States at smokeshops and select gas stations, especially in major cities. The considerably different, sweetened American snus is more commonly found at convenience stores, in multiple brands produced by US-based cigarette companies. Neither product category has made much of an inroad into the market-share held by the dipping tobacco products more common in that country.

Snus has been scrutinized for its potential effect on oral microbiota.[50] Oral microbiota, consisting of microorganisms in the oral cavity, plays a crucial role in maintaining oral health. Imbalances in oral microbiota can lead to oral health issues, with various factors, including tobacco use, influencing this balance.

While research has indicated that smoking significantly alters oral microbiota,[51] studies on the effects of snus are limited. Preliminary studies suggest that snus may affect the composition and diversity of oral microbiota.[52] Specifically, one study identified differences in the abundance of certain bacterial species between snus users and non-users.

Despite snus usage being associated with conditions like gum recession and tooth discoloration, the connection to severe oral health problems such as periodontal disease and oral cancer remains inconclusive. Nonetheless, snus contains harmful chemicals,[53] including nicotine, which could negatively affect oral health. More research is needed to fully understand snus's effects on oral microbiota and its implications on oral health.

The burning sensation often experienced with snus is caused by the nicotine itself (similar to the tingle of nicotine gum) and some food additives such as sodium carbonate (E500). Sodium carbonate is a food additive used to increase the pH of the tobacco (reduce the acidity). This increases the bioavailability of the nicotine, meaning more is available for absorption. Mucous membranes readily absorb free nicotine. Some flavorings (mints in particular) are astringent and may increase the tingling or burning sensation.

There is some debate among public health researchers over the use of "safer" tobacco or nicotine delivery systems, generally dividing along two lines of thought. Some (primarily in the European Union and Canada) believe in "tobacco harm reduction", with the general belief that while it should remain a goal to reduce addiction to nicotine in the population as a whole, the reduction of harm to the health of those who choose to use nicotine is more pragmatic than the desire to reduce overall nicotine addiction. In other words, people using more harmful forms of tobacco (e.g., cigarettes) should be encouraged to switch to less harmful products (e.g., snus). The other school of thought is that no tobacco product should be promoted, and that attention should be placed instead on getting users to switch to nicotine replacement therapy or quit altogether.

One proponent of using snus for harm reduction is Karl Fagerström, who has a PhD in psychology and is researcher in smoking cessation in Sweden. Some research available today shows snus use reduces or eliminates the risk of cancers associated with the use of other tobacco products, such as chewing tobacco (the type primarily used in the US and Canada, created in a process similar to cigarette tobacco) and cigarettes.[54] The widespread use of snus by Swedish men (estimated at 30% of Swedish male ex-smokers), displacing tobacco smoking and other varieties of snuff, is thought to be responsible for the incidence of tobacco-related mortality in men being significantly lower in Sweden than any other European country . In contrast, since women traditionally are less likely to use snus, their rate of tobacco-related deaths in Sweden can be compared to that of other European countries.

Snus may be less harmful than other tobacco products (see above). According to Kenneth Warner, director of the University of Michigan Tobacco Research Network, "The Swedish government has studied this stuff to death and, to date, there is no compelling evidence that it has any adverse health consequences. … Whatever they eventually find out, it is dramatically less dangerous than smoking."[55]

A 2014 report commissioned by Public Health England on another avenue for tobacco harm reduction, electronic cigarettes, examined the case of snus as "a unique natural experiment in the impact of a socially accepted, non-medical, affordable and easily accessible reduced harm product on the prevalence of tobacco smoking". They concluded that "Although controversial, the Swedish natural experiment demonstrates that despite dual use and primary uptake of the reduced-harm product by young people, availability of reduced-harm alternatives for tobacco smokers can have a beneficial effect. While snus is not likely to become a legal or indeed politically viable option in the UK, this data proves the concept that harm reduction strategies can contribute to significant reductions in smoking prevalence."[56]

Ongoing discussion and debates among primary scientific researchers of the effects of snus use on life expectancy appear to indicate a significant increase in life expectancy among persons who previously smoked tobacco and switch to snus, depending on the age of the persons who switch, even when it is assumed that 100% of the risk of cardiovascular diseases among smokers transfers to snus users. This study determined that "for net harm to occur, 14–25 ex-smokers would have to start using snus to offset the health gain from every smoker who switched to snus."[57] It is also noted, in the correspondence seen in the previous citation,[58][59] that concerns about the effect of marketing by the tobacco industry, as influenced by the results of these scientific studies, is of primary concern to many researchers in the field, including the risk of emboldening the industry to attempt to increase snus sales among young people and promote dual-use of snus and smoked tobacco, and the use of medical nicotine, rather than snus, can better target at-risk populations, given better access and pricing.

However, a growing consensus among researchers of smoking cessation have found nicotine replacement therapy (NRT) products to have limited effectiveness because tobacco users may be seeking the combination of MAO inhibitors (which are found in tobacco) and nicotine, or that NRT products do not deliver sufficient quantities of nicotine. MAO inhibitors in tobacco act to amplify the rewarding effects of nicotine, but may also act as a form of self-medication for people with depression. This could explain the association between mental illness and smoking, but a confounding variable is that chronic nicotine administration itself has been shown to desensitize nicotine receptors over time and lead to antidepressant effects.[60] Smoking cessation itself is strongly associated with reduced depression, anxiety, and stress and improved positive mood and quality of life compared with continuing to smoke.[61] It has been hypothesized that snus' success when compared with conventional NRT as a cigarette substitute could be attributed to its MAO inhibiting properties. However, studies seem to suggest that for MAO inhibition, tobacco has to be pyrolysized (i.e., ignited as in cigarettes, cigars, and pipes). The competing theory is that the success of snus as a smoking alternative is due to its ability to deliver nicotine similar to that acquired through cigarettes, and twice as high as that acquired through NRT.[62] Furthermore, the use of snus, similar to cigarettes, offers a choice of brand, aesthetic rituals of use, and tastes of tobacco and thus has sensory effects that NRT products perhaps lack.

The use of daily snus for smoking cessation has had a 54% success rate for complete abstinence, and a 60% success rate for great reduction in cigarette consumption.[63]

Opponents of snus sales maintain, nevertheless, that even the low nitrosamine levels in snus cannot be completely risk-free, but snus proponents point out that, inasmuch as snus is used as a substitute for smoking or a means to quit smoking, the net overall effect is positive, similar to the effect of nicotine patches.[64]

In addition, this eliminates any exposure to second-hand smoke, further reducing possible harm to other non-tobacco users. This is seen by public health advocates who believe in "harm reduction" as a reason for recommending snus, as well as other NRTs, rather than continued use of methods of tobacco consumption that result in second-hand smoke.

This does not, however, eliminate any harm to health caused by the nicotine itself. Current research focuses on possible long-term side effects of nicotine on blood pressure, hypertension, and possible risk of pancreatic cancer due to tobacco-specific nitrosamines (TSNAs). TSNAs are the only component of tobacco shown to induce pancreatic cancer in laboratory animals.[65] Nicotine may also exacerbate pancreatic illness, because nicotine stimulates the gastrointestinal tract's production of cholecystokinin, which stimulates pancreatic growth and may be implicated in pancreatic cancer. Thus far, the evidence specifically implicating snus in pancreatic cancer is only suggestive.[66][67] Notably, the probability of developing pancreatic cancer from cigarettes is higher than the suggested chance of developing pancreatic cancer from snus.[68][69]

The effect of Swedish snus on blood pressure has been studied at Umeå University in a randomly selected population sample of 4,305 Swedish men between the ages of 25 and 74. In the study, published in November 2008, the researchers found no elevation of blood pressure in snus users who had never been smokers compared to tobacco nonusers.[70]

• Hergens, Maria-Pia; Ahlbom, Anders; Andersson, Tomas; Pershagen, Göran (2005). "Swedish Moist Snuff and Myocardial Infarction Among Men". Epidemiology. 16 (1): 12–6. doi:10.1097/01.ede.0000147108.92895.ba. PMID 15613940. S2CID 37661792.
• Broadstock, Marita (February 2007). "Cardiovascular disease" (PDF). Systematic review of the health effects of modified smokeless tobacco products. New Zealand Health Technology Assessment Report. Vol. 10. pp. 37–56.

• Eliasson, M.; Asplund, K.; Nasic, S.; Rodu, B. (2004). "Influence of smoking and snus on the prevalence and incidence of type 2 diabetes amongst men: The northern Sweden MONICA study". Journal of Internal Medicine. 256 (2): 101–10. doi:10.1111/j.1365-2796.2004.01344.x. PMID 15257722. S2CID 8298507.

• Luo, Juhua; Ye, Weimin; Zendehdel, Kazem; Adami, Johanna; Adami, Hans-Olov; Boffetta, Paolo; Nyrén, Olof (2007). "Oral use of Swedish moist snuff (snus) and risk for cancer of the mouth, lung, and pancreas in male construction workers: A retrospective cohort study". The Lancet. 369 (9578): 2015–20. doi:10.1016/S0140-6736(07)60678-3. hdl:11585/682489. PMID 17498797. S2CID 6676039.
• Roosaar, Ann; Johansson, Anna L.V.; Sandborgh-Englund, Gunilla; Axéll, Tony; Nyrén, Olof (2008). "Cancer and mortality among users and nonusers of snus". International Journal of Cancer. 123 (1): 168–73. doi:10.1002/ijc.23469. PMID 18412245. S2CID 6667256.

• Gilljam, Hans; Galanti, M. Rosaria; Swedish Cancer, Society; Pharmacia, AB (2003). "Role of snus (oral moist snuff ) in smoking cessation and smoking reduction in Sweden". Addiction. 98 (9): 1183–9. doi:10.1046/j.1360-0443.2003.00379.x. PMID 12930201. S2CID 28452155.
• Rodu, Brad; Godshall, William T (2006). "Tobacco harm reduction: An alternative cessation strategy for inveterate smokers". Harm Reduction Journal. 3: 37. doi:10.1186/1477-7517-3-37. PMC 1779270. PMID 17184539.

• Asplund, Kjell (October 29, 2002). Snuffing, Smoking and the risk for heart disease and other vascular diseases (PDF) (3rd ed.). Action on Smoking and Health.
• The 3rd (2002) International Conference on Smokeless Tobacco – Daily Media Summaries from the U.S. National Cancer Institute
• Discussion of Tomar, S L; Connolly, GN; Wilkenfeld, J; Henningfield, JE (2003). "Declining smoking in Sweden: Is Swedish Match getting the credit for Swedish tobacco control's efforts?". Tobacco Control. 12 (4): 368–71. doi:10.1136/tc.12.4.368. PMC 1747795. PMID 14660769.
• Kozlowski, L T; O'Connor, RJ; Edwards, BQ (2003). "Some practical points on harm reduction: What to tell your lawmaker and what to tell your brother about Swedish snus". Tobacco Control. 12 (4): 372–3. doi:10.1136/tc.12.4.372. PMC 1747799. PMID 14660770.